User profiles for H. Adamali
Huzaifa I AdamaliBristol Interstitial Lung Disease (BILD) Service, North Bristol Lung Center, Southmead Verified email at nbt.nhs.uk Cited by 7205 |
Use of transbronchial cryobiopsy in the diagnosis of interstitial lung disease—a systematic review and cost analysis
C Sharp, M McCabe, H Adamali… - QJM: An International …, 2017 - academic.oup.com
Background: Histological diagnosis by surgical lung biopsy for interstitial lung disease (ILD)
is currently limited. Transbronchial cryobiopsy via flexible bronchoscope may this for more …
is currently limited. Transbronchial cryobiopsy via flexible bronchoscope may this for more …
[HTML][HTML] Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …
hospitalisation with acute disease is not well understood. The aim of this study was to …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, J Adabie-Ankrah, F Adam, M Adam, H Adamali… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods This …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods This …
Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort
The longer-term consequences of SARS-CoV-2 infection are uncertain. Consecutive patients
hospitalised with COVID-19 were prospectively recruited to this observational study (n=163…
hospitalised with COVID-19 were prospectively recruited to this observational study (n=163…
Current and novel drug therapies for idiopathic pulmonary fibrosis
HI Adamali, TM Maher - Drug Design, Development and Therapy, 2012 - Taylor & Francis
Over the past decade, there has been a cohesive effort from patients, physicians, clinical and
basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic …
basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic …
[HTML][HTML] Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective …
…, LV Wain, CE Brightling, K Abel, H Adamali… - The Lancet …, 2022 - thelancet.com
Background No effective pharmacological or non-pharmacological interventions exist for
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …
Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study
… Huzaifa Adamali … Huzaifa Adamali … Enomoto N, Naoi H, Aono Y, Katsumata M, Horiike Y,
Yasui H, et al. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison …
Yasui H, et al. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison …
Ambulatory and short‐burst oxygen for interstitial lung disease
C Sharp, H Adamali, AB Millar - Cochrane Database of …, 2016 - cochranelibrary.com
Background A large subgroup of people with interstitial lung disease (ILD) are normoxic at
rest, but rapidly desaturate on exertion. This can limit exercise capacity and worsen dyspnoea…
rest, but rapidly desaturate on exertion. This can limit exercise capacity and worsen dyspnoea…
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled …
…, PG Cox, KR Flaherty, HI Adamali… - The Lancet …, 2023 - thelancet.com
Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…
[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
…, S Adair, F Adam, M Adam, H Adamali… - The Lancet, 2021 - thelancet.com
Background Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2
antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma …
antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma …